C/EBPbeta Isoforms - An Innovative Transcription Factor Therapy for Breast Cancer
Abstract
The transcription factor C/EBPbeta, is critical for growth and differentiation of the mammary gland. Three forms of C/EBPbeta are expressed in cells through alternative translation of the C/EBPbeta mRNA. C/EBPbeta.l and -2 activate transcription; C/EBPbeta-2 is a truncated form that represses transcription. flased upon their distinct expression patterns in normal and transformed cells as well as functional studies, we propose that C/EBPbeta-l and -3 (or both) will be potent anti-tumor therapies when used either singly or in combination by suppressing the expression of genes which drive the cell cycle (C/EBPbeta-3) and/or reactivating a differentiation program (C/EBPbeta-l). The purpose of this study is to develop non-replicating murine retroviral and adenoviral vectors carrying genes selectively encoding either C/ElBPbeta-l or -3. These vectors will be used to efficiently re-express C/EBPbeta-l and/or overexpress C/EBPbeta-3 in breast cancer cells lines and evaluate the growth potential of the cells. We have successfully generated murine retroviral vectors encoding C/EBPbeta-l and C/EBPbeta-3 as well as an adenovirus encoding C/EBPbeta-3. We have infected breast cancer cell lines with each of these viruses and documented nuclear expression of C/EBPbeta-l and -3 by both immunohistochemistry and immunoblotting. Studies on the growth potential of the infected cells are confidential and will be presented in the annual report.
Document Details
- Document Type
- Technical Report
- Publication Date
- May 01, 2003
- Accession Number
- ADA417240
Entities
People
- Linda J. Sealy
Organizations
- Vanderbilt University Medical Center